Correction : Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations

Web of Science: 0 citas, Scopus: 0 citas, Google Scholar: citas,

(Medical University of South Carolina)
Wyman-Chick, Kathryn A. (HealthPartners)
Abdelnour, Carla

(Universitat Autònoma de Barcelona)
Toledo, Jon B. (University of Florida)
Ferreira, Daniel (Mayo Clinic)
Urwyler, Prabitha (University of Bern)
Weil, Rimona S. (University College London)
Kane, Joseph (Queen's University)
Pilotto, Andrea (University of Brescia)
Rongve, Arvid

(The University of Bergen)
Boeve, Bradley (Mayo Clinic)
Taylor, John-Paul (Newcastle University)
McKeith, Ian (Newcastle University)
Aarsland, Dag

(King's College London)
Lewis, Simon J. G. (University of Sydney)

Fecha:	2022
Resumen:	The selection of appropriate outcome measures is fundamental to the design of any successful clinical trial. Although dementia with Lewy bodies (DLB) is one of the most common neurodegenerative conditions, assessment of therapeutic benefit in clinical trials often relies on tools developed for other conditions, such as Alzheimer's or Parkinson's disease. These may not be sufficiently valid or sensitive to treatment changes in DLB, decreasing their utility. In this review, we discuss the limitations and strengths of selected available tools used to measure DLB-associated outcomes in clinical trials and highlight the potential roles for more specific objective measures. We emphasize that the existing outcome measures require validation in the DLB population and that DLB-specific outcomes need to be developed. Finally, we highlight how the selection of outcome measures may vary between symptomatic and disease-modifying therapy trials.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Clinical trials ; Dementia with Lewy bodies ; Measurement properties ; Outcomes
Publicado en:	Translational Neurodegeneration, Vol. 11 (may 2022) , ISSN 2047-9158

1 p, 574.4 KB

Registro creado el 2023-11-08, última modificación el 2023-11-22